Company: INMB
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003354
Chunk: 165

Company: Inmune Bio, Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1A
Chunk 165
---
 business plan. If we are not able to raise sufficient capital
in the near future, our continued operations will be in jeopardy and we may be forced to cease operations and sell or otherwise transfer
all or substantially all of our remaining assets.

We face intense competition in the markets
targeted by our lead product candidates. Many of our competitors have substantially greater resources than we do, and we expect that all
of our product candidates under development will face intense competition from existing or future drugs. 

We expect that our product
candidates under development, if approved, will face intense competition from existing and future drugs marketed by large companies. These
competitors may successfully market products that compete with our products, successfully identify drug candidates or develop products
earlier than we do, or develop products that are more effective, have fewer side effects or cost less than our products, if any.

Additionally, if a competitor
receives FDA approval before we do for a drug that is similar to one of our product candidates, FDA approval for our product candidate
may be precluded or delayed due to periods of non-patent exclusivity and/or the listing with the FDA by the competitor of patents covering
its newly-approved drug product. Periods of non-patent exclusivity for new versions of existing drugs such as our current product candidates
can extend up to three and one-half years. See the section entitled “Government Regulation.”

These competitive factors
could require us to conduct substantial new research and development activities to establish new product targets, which would be costly
and time-consuming. These activities would adversely affect our ability to commercialize products and achieve revenue and profits.

30

Competition and technological change may
make our product candidates and technologies less attractive or obsolete.

We compete with established
pharmaceutical and biotechnology companies that are pursuing other forms of treatment for the same indications we are pursuing and that
have greater financial and other resources. Other companies may succeed in developing products earlier than us, obtaining FDA approval
for products more rapidly, or developing products that are more effective than our product candidates. Research and development by others
may render our technology or product candidates obsolete or noncompetitive or result in treatments or cures superior to any therapy we
develop. We face competition from companies that internally develop competing technology or acquire competing technology from universities
and other research institutions. As these companies develop their technologies, they may develop competitive positions that may prevent,
make futile, or limit our product commercialization efforts, which would result in a decrease in the revenue we would